Expert compares PSMA imaging agents, discusses PSMA vs Axumin in prostate cancerNovember 12th 2021
Now that there are 2 FDA-approved PSMA-PET imaging agents, urologists and other clinicians are asking about the differences between them, as well as how PSMA-PET imaging compares to the previously approved next-generation imaging agent fluciclovine F 18.
Adding PSMA PET/CT imaging to mpMRI improves detection of significant prostate cancerOctober 28th 2021
"Combining mpMRI and 68Ga-PSMA PET/CT in a primary diagnostic setting could better identify where to target on biopsy, increasing the diagnostic yield, improving concordance with underlying tumor grade and therefore improving management recommendations," the authors wrote.
IL-15 superagonist N-803 shows strong clinical activity in papillary NMIBCOctober 20th 2021
Data from the phase 2/3 QUILT-3.032 trial showed that adding N-803 to BCG met the primary end point of disease-free survival in patients with BCG-unresponsive, high-grade non–muscle-invasive bladder cancer and papillary disease.
Optilume drug-coated balloon superior to standard care for recurrent anterior urethral stricturesOctober 14th 2021
“Optilume exhibited a significant improvement in [the primary] objective outcome at 6 months and subjective outcomes at 1-year post treatment compared to standard of care,” said Justin Chee, MBBS, FRACS.
UGN-102 effective in patients with low-grade NMIBCOctober 5th 2021
The significant treatment response and sustained durability observed in this trial indicate that UGN-102 has the potential to become a nonsurgical alternative for these chronically relapsing patients, who typically undergo repetitive surgeries,” said William C. Huang, MD.
Enfortumab vedotin approved in Japan for bladder cancerSeptember 27th 2021
The approval was primarily supported by data from the phase 3 EV-301 trial, in which enfortumab vedotin reduced the risk of death by 30% versus chemotherapy in patients with heavily pretreated locally advanced or metastatic urothelial carcinoma.